BioSpace News Archive

Context Therapeutics Inc. Today announced that on March 28, 2024, the Company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to begin a first-in-human clinical study of CTIM-76.

GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the fiscal year ended December 31, 2023 and provided a corporate update.

Zai Lab Limited partner Bristol Myers Squibb announced the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI® as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer harboring a KRASG12C mutation, met the primary endpoint of progression-free survival and the key secondary endpoint of overall response rate as assessed by Blinded Independent Central Review at final analysis for these endpoints.

aTyr Pharma, Inc. today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2024.

BrainStorm Cell Therapeutics Inc. today announced financial results for the full year ended December 31, 2023 and provided a corporate update.

Xcell Biosciences Inc. today announced it has added new elements to its research collaboration agreement with Labcorp, a global leader of innovative and comprehensive laboratory services.

KBI Biopharma, Inc., a JSR Life Sciences company and cGMP contract development and manufacturing organization, announced the appointment of Peter Carbone as the new Chief Quality Officer, strengthening KBI’s expertise in Quality and Regulatory Affairs.

PharmaEssentia USA Corporation, a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced the publication of an original article in the British Journal of Clinical Pharmacology, “Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.”

Aculys Pharma, Inc. announces the appointment of Hidemasa Tanigaki as Chief Executive Officer and Representative Director, effective March 29th.

Foresee Pharmaceuticals, announces the positive safety review by the independent Data and Safety Monitoring Board for its Casppian Phase 3 registration study.